Literature DB >> 16278675

Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo.

J Yuan1, A Krämer, Y Matthess, R Yan, B Spänkuch, R Gätje, R Knecht, M Kaufmann, K Strebhardt.   

Abstract

Cyclin B1 is the regulatory subunit of cyclin-dependent kinase 1 (Cdk1) and is critical for the initiation of mitosis. Accumulating data indicate that the deregulation of cyclin B1 is tightly linked to neoplastic transformation. To study the phenotype and the potential preclinical relevance, we generated HeLa cell lines stably transfected with the plasmids encompassing short hairpin RNA (shRNA) targeting cyclin B1. We demonstrate that the reduction of cyclin B1 caused inhibition of proliferation by arresting cells in G2 phase and by inducing apoptosis. Cells, entering mitosis, were impaired in chromosome condensation and alignment. Importantly, HeLa cells with reduced cyclin B1 were more susceptible to the treatment of small interfering RNA targeting Polo-like kinase 1 (Plk1) and to the administration of the chemotherapeutic agent taxol. Finally, HeLa cells with reduced cyclin B1 showed inhibited tumor growth in nude mice compared to that of control cells. In summary, our data indicate that cyclin B1 is an essential molecule for tumor cell survival and aggressive proliferation, suggesting that the downregulation of cyclin B1, especially in combination with other molecular targets, might become an interesting strategy for antitumor intervention.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16278675     DOI: 10.1038/sj.onc.1209202

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  53 in total

1.  Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo.

Authors:  Juping Yuan; Mourad Sanhaji; Andrea Krämer; Wolfgang Reindl; Matthias Hofmann; Nina-Naomi Kreis; Brigitte Zimmer; Thorsten Berg; Klaus Strebhardt
Journal:  Am J Pathol       Date:  2011-08-10       Impact factor: 4.307

2.  Primate-specific RFPL1 gene controls cell-cycle progression through cyclin B1/Cdc2 degradation.

Authors:  J Bonnefont; T Laforge; O Plastre; B Beck; S Sorce; C Dehay; K-H Krause
Journal:  Cell Death Differ       Date:  2010-08-20       Impact factor: 15.828

3.  In vitro growth inhibition of human cancer cells by novel honokiol analogs.

Authors:  Jyh Ming Lin; A S Prakasha Gowda; Arun K Sharma; Shantu Amin
Journal:  Bioorg Med Chem       Date:  2012-04-03       Impact factor: 3.641

4.  Bioinformatics analysis of the target gene of fibroblast growth factor receptor 3 in bladder cancer and associated molecular mechanisms.

Authors:  Xing Ai; Zhuo-Min Jia; Juan Wang; Gui-Ping DI; X U Zhang; Fengling Sun; Tong Zang; Xiumei Liao
Journal:  Oncol Lett       Date:  2015-05-19       Impact factor: 2.967

5.  Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles.

Authors:  Carlee E Ashley; Eric C Carnes; Genevieve K Phillips; Paul N Durfee; Mekensey D Buley; Christopher A Lino; David P Padilla; Brandy Phillips; Mark B Carter; Cheryl L Willman; C Jeffrey Brinker; Jerri do Carmo Caldeira; Bryce Chackerian; Walker Wharton; David S Peabody
Journal:  ACS Nano       Date:  2011-06-07       Impact factor: 15.881

6.  Functional and spatial regulation of mitotic centromere-associated kinesin by cyclin-dependent kinase 1.

Authors:  Mourad Sanhaji; Claire Therese Friel; Nina-Naomi Kreis; Andrea Krämer; Claudia Martin; Jonathon Howard; Klaus Strebhardt; Juping Yuan
Journal:  Mol Cell Biol       Date:  2010-04-05       Impact factor: 4.272

7.  Silencing PSME3 induces colorectal cancer radiosensitivity by downregulating the expression of cyclin B1 and CKD1.

Authors:  Wen Song; Cuiping Guo; Jianxiong Chen; Shiyu Duan; Yukun Hu; Ying Zou; Honggang Chi; Jian Geng; Jun Zhou
Journal:  Exp Biol Med (Maywood)       Date:  2019-10-20

8.  Thromboxane A2 Receptor Inhibition Suppresses Multiple Myeloma Cell Proliferation by Inducing p38/c-Jun N-terminal Kinase (JNK) Mitogen-activated Protein Kinase (MAPK)-mediated G2/M Progression Delay and Cell Apoptosis.

Authors:  Qian Liu; Bo Tao; Guizhu Liu; Guilin Chen; Qian Zhu; Ying Yu; Yu Yu; Hong Xiong
Journal:  J Biol Chem       Date:  2016-01-02       Impact factor: 5.157

9.  Inhibitory effects of Arhgap6 on cervical carcinoma cells.

Authors:  Junping Li; Yang Liu; Yihua Yin
Journal:  Tumour Biol       Date:  2015-12-01

10.  Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth.

Authors:  Laurence Crombez; May Catherine Morris; Sandrine Dufort; Gudrun Aldrian-Herrada; Quan Nguyen; Gary Mc Master; Jean-Luc Coll; Frederic Heitz; Gilles Divita
Journal:  Nucleic Acids Res       Date:  2009-05-29       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.